VARI International is currently exploring potential collaborations in Australia, Sweden, Malaysia, France, and Japan. We hope to establish research centers in these and other countries dedicated to various medical areas such as neuroscience, molecular medicine, metabolic syndrome, and drug development. Our current global initiatives include: In Singapore, a collaboration agreement between National Cancer Centre of Singapore and VARI was established in July 2006 to implement the NCCS-VARI Translational Research Program focused on the development of cancer treatments. Under the leadership of Drs. Bin T. Teh and Kyle A. Furge serving as Co-Directors of the program, Dr. Koo Wen Hsin, head of medical oncology at NCCS, will provide oversight and management of clinical issues involved in the studies. In China, a partnership has recently been established with Fudan University in Shanghai through the Fudan-VARI Center for Genetic Epidemiology. Led by VARI Senior Scientific Investigator Dr. Jianfeng Xu, the new center will identify the genetic basis of cancers and other complex diseases in Chinese populations and will use genetic information to develop strategies for disease risk-prediction, early diagnosis, and personalized treatments, of benefit to China and the rest of the world. Our newly established VARI-Shanghai Ltd, located in the heart of the Zhangjiang High-Tech Park where over 900 companies in the pharmaceutical, bio-tech and information technology are located, will offer a new dimension to VARI in scientific and medical research with invaluable resources and innovations. |
|
